Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

about

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

Item

http://www.wikidata.org/entity/Q35721504

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

@ast

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

@en

type

Item

label

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

@ast

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

@en

prefLabel

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

@ast

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.

@en

P1476

Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting

@en

P2093

A A Belogurov

http://www.w3.org/2001/XMLSchema#string

A A Ovsepyan

http://www.w3.org/2001/XMLSchema#string

A G Gabibov

http://www.w3.org/2001/XMLSchema#string

A V Stepanov

http://www.w3.org/2001/XMLSchema#string

G B Telegin

http://www.w3.org/2001/XMLSchema#string

N A Ponomarenko

http://www.w3.org/2001/XMLSchema#string

O G Shamborant

http://www.w3.org/2001/XMLSchema#string

P Kothapalli

http://www.w3.org/2001/XMLSchema#string

S M Deyev

http://www.w3.org/2001/XMLSchema#string

V D Knorre

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple sclerosis-a quiet revolution

Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review

Modern Technologies for Creating Synthetic Antibodies for Clinical application.

Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis.

The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.

Design of targeted B cell killing agents.

Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen.

Incidence and prevalence of multiple sclerosis in Europe: a systematic review

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

P304

74-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Srini V Kaveri

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26085947

http://www.w3.org/2001/XMLSchema#string

P932

4463415

http://www.w3.org/2001/XMLSchema#string